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This review aimed to answer whether the vasopressors are useful at the early phase of hemorrhagic shock. Data
were taken from published experimental studies and clinical trials. Published case reports were discarded. A search
of electronic database PubMed was conducted using keywords of hemorrhagic shock, vasopressors,
vasoconstrictors, norepinephrine, epinephrine, vasopressin. The redundant papers were not included. We identified
15 experimental studies that compared hemorrhagic shock resuscitated with or without vasopressors, three
retrospective clinical studies, and one controlled trial. The experimental and clinical studies are discussed in the
clinical context, and their strengths as well as limitations are highlighted. There is a strong rationale for a
vasopressor support in severe hemorrhagic shock. However, this should be tempered by the risk of excessive
vasoconstriction during such hypovolemic state. The experimental models must be analyzed within their own limits
and cannot be directly translated into clinical practice. In addition, because of many biases, the results of clinical
trials are debatable. Therefore, based on current information, further clinical trials comparing early vasopressor
support plus fluid resuscitation versus fluid resuscitation alone are warranted.
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Introduction
The use of vasopressors, such as norepinephrine for
the hemodynamic management of hemorrhagic shock,
may be considered in the early phase of resuscitation
and is a common practice among several prehospital
and hospital emergency teams in Europe except in the
United Kingdom [1]. Nevertheless, it is worth noting
that there is no mention of vasopressor use in North
American textbooks and European recommendations
[2,3]. Thus, it seems legitimate to question the appro-
priateness of its use as well as the choice of the drug to
be used. In this article, we will first attempt to under-
stand whether there are physiopathological arguments
justifying vasopressor use during hemorrhagic shock.
Next, our purpose is to scrutinize data stemming from
animal experiments. Lastly, we will analyze the few hu-
man studies on this subject published thus far. Be aware* Correspondence: piasfar@chu-angers.fr
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in any medium, provided the original work is pthat the goal of our investigation is not to debate about
the hemodynamic endpoints notably in terms of blood
pressure to be achieved during hemorrhagic shock resus-
citation according to the different phases, namely the
prehospital phase, the phase preceding hemorrhage con-
trol, and lastly the phase following hemorrhage control.
Methods
Data source
Published experimental studies and clinical trials. Pub-
lished case reports were discarded.
Data extraction
A search of the electronic database PubMed was con-
ducted using the keywords of hemorrhagic shock, vaso-
pressors, vasoconstrictors, norepinephrine, epinephrine,
and vasopressin. The redundant papers were not included.
Data synthesis
We identified 15 experimental studies that compared
hemorrhagic shock resuscitated with or without vaso-
pressors, three retrospective clinical studies, and one
controlled trial. Given the great heterogeneity in thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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formal metaanalysis. Therefore, experimental and clin-
ical studies are discussed in the clinical context and their
strengths as well as limitations are highlighted.
Physiopathological arguments for vasopressor
support in hemorrhagic shock
The early phase of hemorrhage is characterized by sym-
pathetic system activation resulting in compensatory
venous and arterial vasoconstriction, aimed at normaliz-
ing arterial blood pressure [4]. Initially, this mechanism
is deemed efficacious. Animal experiments have even
shown that when retransfusing the shed blood volume,
previously withdrawn to produce hemorrhagic shock,
arterial blood pressure values exceed those observed at
baseline, underlining the performance and efficiency of
compensatory mechanisms. Therefore, vasopressor sup-
port at this stage does not appear to be indicated [5].
However, several subsequent events are bound to pro-
gressively or brutally alter this vasoconstrictive vessel
response. Beyond a certain amount of blood loss, sym-
pathetic inhibition occurs, leading to a drop in vascular
resistances and bradycardia, rapidly followed by cardio-
circulatory arrest. During this phase immediately preced-
ing cardiac arrest, and a fortiori in the case of cardiac
arrest, the usefulness of rapid vasopressor injection to
restore arterial blood pressure and redirect cardiac out-
put toward vital organs is undisputable. Well before this
phase of extreme exsanguination, animal models show
that anesthetic agents exert a significant effect on the
vasoconstrictive response to hemorrhage and that stable
and normal blood pressure values seen in conscious ani-
mals are no longer observed in anesthetized animals fol-
lowing withdrawal of similar blood volumes [6]. In this
context, it is important to remind that the majority of
patients with hemorrhagic shock require the use of such
agents to obtain analgesia or sedation for ventilatory
intubation during shock management or before surgical
intervention or embolization. Shock duration also is
likely to modify the vasoconstrictive response. While in
animal experiments involving short-duration hemor-
rhagic shock, the retransfusion of shed blood resulted in
higher arterial blood pressure than baseline as previously
mentioned, in long-duration shock exposure exceeding
several hours, blood retransfusion alone does not allow
arterial blood pressure to return to baseline values. This
absence of normalization of blood pressure values sug-
gests vasodilation, as seen in prolonged states of shock
characterized by a deficiency of compensatory mecha-
nisms [7]. In addition, an intense inflammatory response
may develop in hemorrhagic shocks [8]. Blood with-
drawal may cause global ischemia-reperfusion injuries
resulting in up-regulation of cytokine expression [9] and
oxidative and nitrosative stresses [10]. Thus, in a modelof anesthetized rats, hemorrhagic shock led to a vascular
hyporeactivity to norepinephrine mediated by an en-
hanced release of nitric oxide (NO), such as in septic
shock [11]. Therefore, in such a context of insufficient
vasoconstriction or even vasoplegia, vasopressor support
seems justified. However, the difficulty when extrapolat-
ing animal data to humans must be stressed, as far as
timing for vasopressor support is concerned.
In addition to their usefulness in the case of vasodila-
tation or insufficient vasoconstriction, vasopressors may
be useful to restore hemodynamic parameters along with
adequate vital organ infusion, thereby reducing the need
for continuous fluid infusion, which may result in
side-effects, such as tissue edema. The occurrence of a
systemic inflammatory response, in particular an acute
respiratory distress syndrome (ARDS), appears to be the
primary cause of death on Day 3 in trauma patients [12].
In a series of 102 severely traumatized patients, the infu-
sion of crystalloid solutions during the first 24 hours
was associated with subsequent aggravation of pulmon-
ary dysfunction [13]. Whilst in this study no direct
causal relationship between fluid loading and pulmonary
lesions could be established, limitation of sodium-water
load during the initial resuscitation phase afforded by
the vasoconstrictor use may be associated with beneficial
effects during the secondary systemic inflammatory
phase. It is probable that this is an entirely new indi-
cation for early vasopressor support. In addition, the
benefits of a strategy based on vasopressor use and com-
bining volume-sparing and optimized arterial blood
pressure might have a positive impact on the progres-
sion of cerebral lesions (limitation of cerebral edema;
maintenance of high infusion pressure), keeping in mind
that cerebral lesions are eventually the first cause of
death in trauma patients [12] and that even a single,
brief episode of hypotension may worsen mortality [14].
Furthermore, in severely hypotensive patients with septic
shock, Hamzaoui et al. showed that early administration
of norepinephrine increased cardiac output, mediated
by an increased cardiac preload likely due to venous
constriction and by an increased cardiac contractility
[15]. A similar effect may be expected in patients with
hemorrhagic shock.
Lastly, in the case of abdominal lesions, early vaso-
pressor infusion allowing portal output to decrease via
splanchnic vasoconstriction (this effect being particularly
pronounced following vasopressin use) is likely to result
in decreased hemorrhagic loss from splanchnic blood
vessels, while maintaining adequate infusion of other
organs.
The question raised regarding vasopressor support for
hemorrhagic shock is perhaps somewhat simplified,
because it places all trauma and even all polytrauma pa-
tients under the same label of hemorrhagic shock. Shock
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from single, hemorrhagic lesion. In these cases, the
problem is not only hemorrhage, but also the multiple
tissue injuries associated with prolonged shock, due to
both hypovolemia as well as alveolar and tissue hyp-
oxia, which subsequently trigger a hyperinflammatory
response [16,17]. In this situation, vasopressor support
at the very early stage appears particularly appropriate.
To illustrate this, we refer to a clinical study in which
vasoplegia and cardiac dysfunction were already noted
in polytrauma patients at a very early stage, upon emer-
gency room admission [16].
Although theoretically tempting, these concepts argu-
ing for vasopressor support for hemorrhagic shock are
only speculative, and animal and human studies must be
further scrutinized to determine whether vasopressor
agents are efficacious and at the same time devoid of
detrimental ischemic side-effects.
Experimental data
In animal models, when given at the early stage, vasopres-
sors were shown to be capable of restoring a quasi-normal
hemodynamic status by mobilizing nonconstraint venous
blood volume and thus normalizing arterial blood pres-
sure, cardiac output, and preload parameters, such as
pulse pressure variations [18]. However, the consequences
of such a masked hypovolemia are far from insignificant.
In an experimental hemorrhage model associated with
endotoxin injection, Hinder et al. investigated the effects
of norfenefrine, a pure vasopressor [19]. These authors
demonstrated that norfenefrine infusion, even in the ab-
sence of concomitant fluid loading, resulted in normalized
filling pressures. This masked hypovolemia was associated
with disseminated cardiac cell necrosis and severe acute
renal dysfunction. This adverse effect is likely to be dose-
dependent as reported by Poloujadoff et al. [20]. In this
study, norepinephrine in combination with saline infusion
in uncontrolled hemorrhagic shock in rats was associated
with improved survival. But irrespective to the threshold
of lower MAP (40 mm Hg versus 80 mmHg), the highest
dose of norepinephrine was associated with increased
mortality rate. These recent findings confirm those ob-
tained in older studies, suggesting the deleterious effects
of vasopressor use in experimental hemorrhage models,
due to the worsening of tissue hypoperfusion [21]. Of note
in all of these experimental models, the duration of shock
was brief and vasopressor agents were used alone, most
often without fluid challenge [18,19] at the early shock
stage when arterial vasodilatation was not yet present.
However, in a model of normovolemic hemorrhage in
which pigs received hemodilution until death, maintaining
MAP > 60 mmHg by norepinephrine infusion allowed
for the exchange of a significantly higher volume of
blood [22]. Using the pig model associating uncontrolledhemorrhage (splenic laceration) and cranial trauma,
which is closer to the condition of a polytrauma patient,
Alspaugh et al. have shown that early and isolated
administration of phenylephrine was associated with a
higher survival rate than with crystalloid fluid resuscita-
tion alone, although the cardiac output was decreased
in the phenylephrine group [23]. Of note, the splenic
laceration resulted in large variability in hemorrhage
volume and hemodynamic response of the individual
animal. Using a similar model, Feinstein et al. compared
crystalloid administration alone versus crystalloid +
phenylephrine or vasopressin [24]. Vasopressor support
limited the volume of perfused solutions, decreased pul-
monary lesions, and reduced elevations of intracranial
pressure. Recently, these observations have been con-
firmed using a similar model of cerebral lesions and
hemorrhage, associating fluid infusion and vasopressin
administration [25]. As the studies in head-injured
patients showed that norepinephrine does not alter
intracranial pressure [26,27], this protective effect of
vasopressor infusion on intracranial pressure is likely to
be dependent on the reduction of fluid loading rather
than on a direct effect of the vasoconstrictive drug.
Conversely in a model of uncontrolled hemorrhage
induced by a penetrating liver trauma without brain in-
jury, in comparison with hypertonic hydroxyethyl starch
alone, the addition of norepinephrine did not show
beneficial effect on cerebral perfusion pressure or brain
tissue oxygenation [28]. These last studies underline the
potential usefulness of vasopressor support in condi-
tions where rapid blood pressure restoration is required
(cranial trauma), as well as the effects of volume-
sparing measures on pulmonary lesions and cerebral
edema, and point out the need for initial fluid loading.
Nonetheless, as a decrease in cardiac output and
unfavorable metabolic effects (hyperlactatemia) were
frequently observed in experimental studies associating
fluid infusion and vasopressor support [29], the condi-
tions for using a vasopressor agent along with fluid infu-
sion must be better defined in terms of vasopressor
agent and timing of infusion.
In experimental models of massive hemorrhage, sev-
eral recent studies reported that vasopressin infusion
was associated with survival benefits compared to fluid
administration alone or to other vasopressor agents (epi-
nephrine or norepinephrine) [30-33]. These models are
characterized by a marked drop in arterial pressure
before the initial resuscitation, arterial pressure being
very close to central venous pressure (20 mmHg). In this
context, the use of a vasopressor agent is primarily
aimed at managing cardiac arrest, rather than treating
hemorrhagic shock. Vasopressin may have a role to play
as a lifesaving treatment in the case of hypovolemic cardiac
arrest, designed to restore a satisfactory hemodynamic
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mental data come from the same group that focused their
models on hepatic or other form of abdominal vascular
injury resulting in a hemorrhage located in the splanchnic
vascular bed [30,33,34]. It is thus possible to hypothesize
that vasopressin, while significantly decreasing mesenteric
flow and thus portal flow, might have the advantage of re-
distributing blood flow away from the hemorrhagic lesion
in these models. However, this strategy may impair gut
mucosal perfusion. Indeed, Stadlbauer et al. showed that
infusion of vasopressin was followed by transient diarrhea
during the reperfusion period, suggesting a potential gut
ischemia. However, this side effect was transient and long-
term survival was good [33]. The same team in a similar
animal model also showed that vasopressin infusion did
not result in significant cerebral injury as assessed with
S100B protein measurement [34].
Despite the use of clinical relevant models of hemor-
rhagic shock (in particular by Poloujadoff et al. [20]), the
experimental models are not able to reproduce exactly the
conditions and multiple tissue lesions observed in real
polytrauma patients. Moreover, most animal experiments
only focused on the progression of shock states during a
very short time period rarely exceeding 24 hours. There-
fore, they do not reflect the complexity of a prolonged
ICU stay. In summary, animal data suggest that unreason-
able use of vasopressor agents at excessive doses and with-
out fluid infusion appears to be detrimental. Yet, their use
may be beneficial under better-controlled hemodynamic
conditions. Because outside of these general settings,
experimental animal data are considered incomplete, we
cannot precisely define the conditions for the use of
vasopressor agents.
Clinical studies
To date, no clinical prospective study conducted in the
hemorrhagic shock or traumatology setting compared
different therapeutic strategies with and without vaso-
pressor use. One, single, descriptive study reported on
dopamine use in a general care protocol for polytrauma
patients with life-threatening hemorrhage from pelvic
fractures associating early arteriography ± embolization
along with vasopressor treatment initiated within the
first hour of hospital admission [1]. When comparing
with historical series of similar patients, the outcome
was better with aggressive therapeutic strategies. Because
the vasopressor was administered in association with
multiple other therapeutic bundles, and in absence of
control group, the therapeutic effect of the vasopressor
agent on patient outcome cannot be derived from this
single study. Nevertheless, early use of vasopressor
agents in hemorrhagic shock management was not asso-
ciated with any obvious detrimental effects. Conversely,
in a retrospective study conducted in the United States,early administration of any vasopressor was analyzed in
a multivariable analysis. The authors showed that vaso-
pressor use was associated with increased mortality,
whereas aggressive crystalloid administration was found
to be beneficial [35]. Of note, early deaths were excluded
from analysis, although these very severe patients may
be more likely to benefit from vasopressor infusion.
More recently, Plurad et al. reported in a retrospective
study in 1,349 selected patients without brain or spinal
cord injuries that the early vasopressor use after the crit-
ical injury was associated with a significant increase in
mortality rate regardless of the fluid status. Here too
were only included the patients who had survived more
than 24 hours [36]. Because the patients with early death
may specifically benefit from early vasopressor use, the
exclusion of these patients is a major limitation. These
negative studies were recently challenged by a prospect-
ive study that assessed the effect of early vasopressin use
in a double-blind, randomized trial. Compared with the
control group (fluid alone, 40 patients), the addition of
vasopressin (4 IU bolus followed by 2.4 IU/H for 5H, 38
patients) was associated with lower fluid resuscitation
volume over 5 days (p = 0.04) with a mortality rate at
day 5 of 25% versus 13%, respectively (p = 0.19) [37].
Conclusions
Despite numerous theoretical arguments in favor of the
relatively early vasopressor use in association with fluid
infusion in hemorrhagic shock management, there is still
insufficient clinical evidence to validate this strategy.
Experimental data available to date clearly indicate that
vasopressor support cannot be replaced by fluid loading.
In contrast, when given in association with fluids, the
use of vasopressor agents appears to offer advantages, at
least in some experimental models. Nevertheless, the
type of vasopressor and the precise timing still need to
be defined. Lastly, no clinical studies have validated any
vasopressor support for the management of hemorrhagic
shock. The use of norepinephrine advocated by some
teams appears reasonable, but it must be kept in mind
that this recommendation is entirely based on expert
opinions [38,39]. The North American strategy, which
excludes vasopressors, may be explained by the wide
differences in patients with hemorrhagic shock. As the
European studies mainly recruited polytrauma patients,
in which the inflammatory response to multiple tissue
lesions begins early and lasts hours to days and often are
associated with cerebral lesions that require achieving
very strict arterial pressure goals, the recommendation
of vasopressor use seems logical. In contrast, the North
American recommendation of fluid loading alone may
be related to a different epidemiologic pattern (frequent
unique penetrating traumatic lesions). In these cases, the
isolated lesion of a blood vessel is much closer to the
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shock,” which require less strict arterial pressure objectives,
while awaiting prompt and final surgical hemostasis [40].
Following this discussion on vasopressor support, one
should acknowledge that fluid loading is the first step to
be considered in the management of hemorrhagic shock.
Based on current information, further clinical studies
that are designed to compare early vasopressor support
plus fluid resuscitation versus fluid resuscitation alone
are warranted. In this context, the prospective European
study conducted to assess the impact of vasopressin
infusion as a salvage therapy in prehospital hemorrhagic
shock that persists despite standard treatment, including
a first line vasopressor (Vasopressin In Traumatic Shock
(VITRIS) trial, NCT00379522), may provide an answer.
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